Veru Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy

2022.04.11 14:26

Veru (VERU) Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy

Veru Inc. (NASDAQ:VERU) shares are gaining over 30% in heavy pre-market trading after the company announced that its COVID-19 drug candidate reduced deaths by 55% in hospitalized COVID patients in Phase 3 trial. Due to the “overwhelming” efficacy of the study, Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 study be halted, and they further remarked that no safety concerns were identified.

Source